The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C01 | Cardiac therapy | |
| 3 | C01C | Cardiac stimulants excl. cardiac glycosides | |
| 4 | C01CA | Adrenergic and dopaminergic agents | |
| 5 | C01CA04 | Dopamine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| PAREN - Parenteral | 0.5 g |
| Active Ingredient | Description | |
|---|---|---|
| Dopamine |
Dopamine hydrochloride stimulates adrenergic receptors of the sympathetic nervous system. Dopamine hydrochloride has principally a direct stimulatory effect on β1-adrenergic receptors, but also appears to have an indirect effect by releasing norepinephrine from its storage sites. Dopamine hydrochloride also appears to act on specific dopaminergic receptors in the renal, mesenteric, coronary, and intracerebral vascular beds to cause vasodilation. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| NEOATRICON Solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.